Loading...

ATYR ATYR PHARMA INC Investments/Divestments 8-K Filing

TYR

TYR

ATYR PHARMA INC

(ATYR)

2023 8-K

Show Summary

Show Summary

Financial Statements

Stock Option Plans

Financial Results

Share Offering Update

Director Appointment

Financial Results

Financial Results

Clinical Trial Enrollment C...

Annual Meeting Approval

Earnings Reports

Earnings Reports

Financial Results Announcement

Investor Conferences

Presentation of Study Results

Financial Results Announcement

Annual Meeting Approval

Financial Results Announcement

Disinvestment of Assets

Financial Results Announcement

Public Offering

Phase 3 Study Milestone

External Links:

aTyr Pharma, Inc. plans to use an investor presentation for meetings and conferences, and has initiated a Phase 2 study of efzofitimod in patients with systemic sclerosis-associated ILD.

AI Assistant

ATYR PHARMA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.